SUMMARY Streptokinase (1 million international units) was given intravenously over 30 or 60 minutes to 50 patients four hours or less after the onset of acute myocardial infarction. All were aged < 70 years and had 4 mm or greater ST segment elevation in anterior or inferior leads. Rapid (mean 95 min) ST segment resolution, which was taken to indicate reperfusion of the myocardium, occurred in 36 (72%) patients. In these 36 the average time from onset of symptoms to peak creatine kinase, creatine kinase MB, and myoglobin was 9 45 hours, whereas it was 17 hours in the 14 patients in whom indirect criteria did not indicate reperfusion. Reperfusion arrhythmias were invariably present and ventricular tachycardia developed in five patients and ventricular fibrillation in two. The infarct related artery was seen to be open in 28 (70%) of the 40 patients who had delayed coronary arteriography. The frequency of patency in the infarct related artery was no different in patients given streptokinase <2 hours or between 2-4 hours from onset of symptoms nor did it differ when streptokinase was infused over 30 or 60 minutes. Mean left ventricular ejection fraction was 57% in those with a patent infarct related artery and 48% in those with an occluded vessel. Eight patients subsequently underwent elective percutaneous transluminal coronary angioplasty after successful thrombolysis and six had coronary artery bypass grafting. There were nine in-hospital reocclusions of the infarct related coronary arteries. Two bleeding episodes occurred; one required transfusion. Five of the 50 patients died in hospital. All of them had had an anterior myocardial infarction; four had bifascicular block and one had right bundle branch block. During follow up, four patients died, two suddenly and two from reinfarction. During follow up (mean 15 months) the frequency of reinfarction, dyspnoea, and angina was low and there was no difference in the proportions of patients returning to work between those with an open infarct related artery and those with a closed infarct related artery.
232 spreads from the subendocardial surface through to the subepicardial surface,7 8 and experimental studies in dogs have shown that early interruption of this destructive advance is likely to offer the best prospect of salvage or recovery in the ischaemic myocardium.9 1O Establishing reperfusion within four hours of complete ischaemia may result in important structural and functional recovery. 1 12 After four hours of complete ischaemia major improvement seems to be unlikely1 12 and reperfusion in such cases possibly only helps to accelerate the decay of already irreversibly injured tissue. The extent of collateral flow, however, is likely to be a major determinant of the time course and final size of infarction in patients. 8 Despite almost two decades of experience, the benefits and risks of administration of intravenous streptokinase in acute myocardial infarction remain to be established. Early randomised studies13 -15 gave equivocal results because populations were heterogenous, treatment was started too late (6-12 hours or more) after the onset of symptoms to be of any benefit, slower infusion times were used, and evidence of reperfusion was not recognised or was misinterpreted.
Intracoronary streptokinase given on average (SD) 4-3 (1-4) hours after acute myocardial infarction was associated with a 76% recanalisation rate in the infarct related artery. 1 6 When intravenous streptokinase was given on average 2-8(1) hours after onset of symptoms, the same workers showed a recanalisation rate of 73%0.16 When intravenous streptokinase was given within six hours of myocardial infarction, early reperfusion, that is within one hour, occurred in 490o of patients. 17 In a similar group of patients Schroder found a patent infarct related artery in 84% at angiography four weeks later.'8 The intravenous route, which does not require emergency arteriography and so is more generally applicable, allows treatment to be started as soon as possible after the onset of symptoms.
We have evaluated the effects of high dose short term intravenous streptokinase in patients presenting within four hours of the onset of acute myocardial infarction and have followed their course after leaving hospital.
Patients and methods
All patients were aged < 70 years, had had symptoms for < 4 hours, and showed an acute injury pattern on Before treatment was started, blood was drawn for a complete blood count, platelet count, prothrombin time, partial thromboplastin time, fibrinogen, total creatine kinase, creatine kinase-MB, and myoglobin. A 12 lead electrocardiogram was recorded. Hydrocortisone (250 mg), given intravenously to prevent an allergic reaction to streptokinase, was followed immediately by a 100 000 IU bolus of streptokinase and then by an infusion of 900 000 IU in 100 ml of physiological saline. Infusion lasted 60 minutes in 20 (400o) patients and over 30 minutes in 30 (60%) patients. After the streptokinase infusion, heparin 40 000 IU was infused over 24 hours. The activated partial thromboplastin time was checked at two, four, eight, 12, and 24 hours after completion of streptokinase administration and the amount of heparin infused was adjusted daily in an attempt to maintain the activated partial thromboplastin time between 80 and 120 s. The infusion of heparin was continued until either delayed coronary arteriography was performed or circumstances dictated otherwise. After arteriography, if angioplasty was not considered, heparin was discontinued and either antiplatelet drugs or warfarin were given daily. After the end of the streptokinase infusion the electrocardiogram was recorded again and thereafter at 30 minutes, one, two, four, eight, 12, 16 , and 24 hours with concurrent measurement of serum creatine kinase, creatine kinase-MB, and myoglobin concentrations. Thereafter electrocardiograms were recorded daily. Coronary arteriography was performed later by the Judkins's transfemoral technique in all except one patient in whom the brachial approach was used. Ejection fraction was assessed in the 300 right anterior oblique projection of the left ventriculogram.
Reperfusion of the myocardium or recanalisation of a recently occluded artery was recognised by (a) rapid decline (>3 mm) of the ST segment injury current on the electrocardiogram; (b) early rise and peak (< 12 hours) in serum creatine kinase, creatine kinase-MB, and myoglobin levels; (c) the occurrence of specific reperfusion arrhythmias-ventricular extrasystoles, runs of idioventricular rhythm, ventricular tachycardia, or ventricular fibrillation; (d) luminal patency of infarct related artery demonstrated at coronary arteriography.
Results
Thrombolysis was attempted in 50 patients (41 male and nine female) aged (mean 57 years); 33 of High dose intravenous streptokinase in acute myocardial infarction-short and long term prognosis There were five (10%) in-hospital deaths (Table  3 ). All the patients had anterior infarction and three had had previous inferior infarctions (average age 60 years, range 43-69). The mean duration of symptoms before streptokinase administration was 136 min (range 120-160). On admission four had bifascicular block and one right bundle branch block and four had pulmonary oedema. None had indirect The major findings in our study were that intravenous high dose streptokinase is a quick, safe, and effective method of achieving thrombolysis in selected patients during the acute phase of myocardial infarction and that 70% of infarct related arteries were patent at angiography. These results compare favourably with other studies in which successful coronary artery recanalisation was achieved in about 75% of patients with myocardial infarction treated by intracoronary streptokinase. 20 Alderman et al in a randomised study of patients with myocardial infarction gave streptokinase within 3-5 hours of the onset of symptoms; the patency rate with intravenous administraton was 62% compared with 73% in those receiving it by the intracoronary route.2 ' Mayer et al found that high dose intravenous streptokinase given an average of 2 77 (1-31) hours from the onset of symptoms gave a patency rate of 83% in the infarct related artery at follow up angiography. 22 Delay, the critical issue determining successful outcome, is minimised by intravenous administration which has the advantage of earlier and easier application in virtually every medical care facility. All our patients had had symptoms for four hours or less and the successful outcome of treatment in those treated within two hours of onset of symptoms (72%) compared favourably with those who were treated after two hours (68%). Thus it would seem reasonable to administer streptokinase to patients within four hours of the onset of acute myocardial infarction when it is-still possible to achieve successful thrombolysis. The shorter streptokinase infusion time of 30 minutes vs 60 minutes was not associated with a significant increase in achieving patency of the infarct related artery (77% vs 61 %).
MacLennan, McMaster, Webb, Khan, Adgey Although the groups were too small to determine the statistical significance of any differences, it was our impression that thrombolysis was more effective in patients with single vessel than in those with double or triple vessel disease (78% vs 54% vs 50%).
Many of these single vessel lesions are accessible to subsequent angioplasty. The occurrence of ventricular fibrillation before thrombolysis should not deter one from attempting to interrupt the natural evolution to complete infarction. Two of the six patients in this study who had ventricular fibrillation before treatment later showed successful recanalisation. In one the rhythm disturbance recurred during treatment. Nevertheless, if human ventricular fibrillation resembles animal ventricular fibrillation then the longer the interval before reperfusion of an occluded vessel is established the less likely is ventricular fibrillation to develop.7 Five patients developed ventricular tachycardia within four hours of thrombolysis. All were treated with conventional antiarrhythmic agents, in none was the arrhythmia fatal, and in all the infarct related artery was patent on angiography. These results indicate that prehospital administration of streptokinase in acute infarction should be considered, so that delay may be avoided and reperfusion be achieved as early as possible. Certainly the potential development of serious ventricular arrhythmias outside hospital should not exclude this therapeutic option.
In this study indirect evidence of reperfusion as demonstrated by accelerated electrocardiographic evolution and peak serum enzyme kinetics correlated well with the subsequent angiographic verification of patency. Both these non-invasive variables are now recognised markers of reperfusion. 16 18 Bleeding complications during the study were infrequent. One patient required a blood transfusion for a retroperitoneal haematoma, which was caused by the heparin infusion rather than streptokinase. No allergic manifestations were seen in response to streptokinase. Five (10%) patients died during hospital stay. All were in the high risk group-that is they all had anterior infarctions, three had had previous inferior infarctions, four had pump failure on admission, and all had conduction abnormalities which were not corrected after streptokinase infusion. None of these patients showed indirect evidence of reperfusion. All were in cardiogenic shock at the time of death, with pump failure and a terminal arrhythmia. Thus the adverse prognosis, well recognised in this particular group of patients, was not improved by attempted thrombolysis.
Four of the 45 patients who survived to leave hospital died (two suddenly, two reinfarction) during follow up. The mortality rate was not higher than expected. For the remaining 41 patients, follow up lasted [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] 
